Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TREVI-OC-01: Phase 3 AZD5335 versus mirvetuximab soravtansine or investigator's choice chemotherapy in platinum-resistant ovarian cancer
MOH_2025-11-30_015507Phase 3Not yet recruiting
- Sponsor
- AstraZeneca
- Start
- Nov 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of AZD5335 in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) (4 arms), sponsored by AstraZeneca. Primary endpoint: Progression-free survival. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
AZD5335
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on MOH_2025-11-30_015507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-11-30_015507.